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Abstract 
Antiphospholipid Syndrome (APS) is an evolving autoimmune disease with numerous clinical 
manifestations. APS occurs in two fonns: Primary Antiphospholipid Syndrome (PAPS) and secondarily in 
association with other autoimmune disorders such as Systemic Lupus Erythematosis (SLE). In the brief 
period since its discovery as a cofactor for anticardiolipin antibodies, p
1
-glycoprotein I (�GPI; 
apolipoprotein H) has been recognized as the autoantigen in the absence of anionic phospholipid when 
appropriately presented to human autoantibodies. Recent studies suggest that this presentation requires the 
surface-dependent unmasking of a cryptic epitope. Immunoassays of autoantibodies directed against 
p1GPI, developed through the application of suitable polymeric matrices, may be clinicaJly relevant in that 
they may be more specific for (APS). Assays of Anti-� Glycoptotein I (aj3
2
GPI) have used a variety of 
materials in the antigen-specific presentation system. This situation renders this assay particularly 
susceptible to interlaboratory variation when raw absorbance data are reported. Presently, many assay 
systems for the detcciion of APS lack standardization and are plagued with technical problems. Reference 
materials for a unifonn enzyme immunoassay oflgG aj31GPI have not, as yet, been available. 
The following thesis focuses on the development and standardization of a clinically significant assay 
for the detection of APS. The assay centers on the detection of a�GPI antibodies. Described herein, is a 
method utilizing commercially available, chemically activated polystyrene microtiter plates with a surface 
-which binds proteins covalently. Additionally, a commercial source of human P,GPI has been obtained. 
Reference caJibrators have been developed consisting of a control group of 111 men and 93 women, 
yielding a range of 0-19 standard lgG antj.j.\GPI units (SGU) for the ninety-fifth percentile of values. 
These are intended as interim calibrators that can be used to develop primary international standards for an 
immunoassay oflgO aP2GPI. 
Introduction 
The study of anti-phospholipid antibodies (aPL) can be traced to the first clinical 
assay for syphilis, developed by Wassennan (1907). Thirty-four years later Pangborn 
(1941), demonstrated that the active antigenic component of the assay was a 
phospholipid, which was named cardiolipin (CL). All subsequent tests were based on the 
detection of antibodies to extracted CL. Thereafter, the venereal disease research 
laboratories (VDRL) antigen assay was created, consisting of a combination of 
cholesterol, phosphatidylcholine (PC) and CL. During the wide use of the assay it 
became apparent that there was a large percentage of the population with positive tests, 
who showed no clinical or epidemiological manifestations of infection. 
This phenomenon was termed biological false positive serological test for syphilis 
(BFP-STS), and occurred under two distinct circumstances. The first BFP-STS were 
detected in a number of patients with infections other than syphilis. The BFP-STS 
�peared with convalescence. Chronic BFP-STS, � an apparently idiopathic origin, 
persisting over many years (Moore and Mohr, 1952). Further studies showed an 
association of chronic BFP-STS and autoimmune diseases. Systemic Lupus 
Erythematosis (SLE) was the major autoimmune disorder associated with chronic BFP­ 
STS (Hasserick and Long, 1951 ). 
Conly and Hartman (1952), described two patients with SLE who had both BFP­ 
STS and an unusual plasma constituent that inhibited in vitro coagulation. Ibis factor 
was termed the lupus anticoagulant (LA) by Feinstein and Rapaport (1972). Detection of 
2 
LA activity was determined by measuring prolonged clotting times in phospholipid­ 
associated coagulation tests; prolonged clotting was indicative of LA. 
The LA is somewhat paradoxical. Lupus anticoagulant was not found in patients 
with syphilis and its association with BFP-STS became widely recognized (Johansson 
and Lassus, 1974). Contrary to the anticoagulant effect observed in vitro these patients 
did not exhibit prolonged bleeding. Bowie and coworkers (1963) reported that patients 
with LA were more prone to thrombosis than to hemorrhage. 
LA consists of a heterogeneous group of antibodies which may require more than 
one clotting test to demonstrate anticoagulant activity (Triplett and Brandt, 1989). Tue 
best method for detecting LA is the subject of some controversy. Tests which are used 
include the following: partial thromboplastin time (PT!), prothrombin time (Pl), 
activated partial thromboplastin time (aPTI), koalin clotting time (K.CI), ·dilute Russel 
viper venom time (dRVVn and tissue thromboplastin inhibition assay (ITI) (Schleider 
ct al., 1976, Rauch ct al., 1989, Triplett and Brandt, 1989, McNeil et al., 1991). 
Furthermore, the LA tests do not distinguish from the antibodies occwring in syphilis and 
those occurring in Primary Antiphospholipid Syndrome (PAPS), SLE and other 
autoimmune disorders. 
This led Thiagarajan and coworkers (1980), to use monoclonal antibodies with lupus 
anticoagulant activity to test the possibility that LA was an antiphospholipid antibody. 
The monoclonal antibodies reacted with several negatively charged pbospholipids, thus 
suggesting that the antibodies may be directed to phospholipid (Thiagarajan ct al., 1980). 
This prompted Harris and colleagues (1983) to develop a solid phase immunoassay to 
directly detect circulating antibodies that bind CL, a negatively charged phospholipid. 
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This enzyme linked immunosorbent assay (ELISA) was developed to improve the 
sensitivity of detecting anti-cardiolipin (aCL) antibodies in patients with SLE. 
The ELISA is perfonned by immobilization of a purified antigen. In ELISA the 
antibody reacts with the immobilized antigen to form an immune complex immobilized 
on the surface. Detection is achieved by reacting the immobilized complex with a SCCQn9 
antibody, which has previously been tagged with a detectable molecule (Ekins, 1971). 
, 
The small serum sample required for the ELISA system provides an advantage over the 
coagulation assay. Using ELISA for aCL Hanis and coworkers (1983) demonstrated a 
majority of LA samples were aCL positive, however, the converse was not true. 
The sensitive immunoassays based on purified cardiolipin stimulated a new era of 
investigation into Antiphospholipid Syndrome (APS), a syndrome characterized by 
arterial and venous thrombosis, strokes, migraines, livedo rcticularis, recurrent fetal loss, 
abortion and thrombocytopenia (Hanis et al., 1983). Initially, aCL antibodies and the LA 
assays were believed to detect antibodies specific for phospholipids or phospholipid- 
protein complexes (Harris et al., 1988), leading to the current nomenclature of the 
syndrome, APS. Antibodies detected in the aCL assay, however, appear to represent an 
immunologically distinct population. Those present in patients with infections such as 
syphilis, leprosy, tuberculosis, and endocarditis the antiphosphoJipid antibodies appear 
not to be associated with vascular spasm (Costello and Green, 1986, Santiago et al., 1989, 
Wang et al., I 995). Additionally aCL antibodies associated with autoimmnne diseases 
were found to react with other anionic phospholipids (McNeil et al., 1991). 
In I 990, it was reported that a CL reactivity by autoantibodies from patients with 
APS was dependent on the presence of a serum protein, apolipoprotein H or 
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p,g!ycoprotein I (P, GP!) (Galli et al., 1990, McNeil et al., 1990). After years of 
controversy over the precise nature of the epitope(s) presented by the cardiolipin-P
2
GPI 
complex, it is apparent that the epitope for the relevant autoantibodies is encrypted in 
circulating �GPI. Several groups have determined that when p
2
GPI is bound to an 
appropriately polar surface, lgG class autoantibodies from subjects with APS recognize 
and bind to the protein. (Matsuura et al., 1994, Keil eJ al., 1995, Roubey et al., 1995). 
Recently it has been established that lgG ap,GPI may be more specific than aCL for APS 
(Balestrieri et al., 1995, Cabiedes et al., 1995, Cabral et al., 1995, El-Kadi et al., 1995, 
Matsuura et al., 1994). 
PlGPI is a 48kd phospholipid binding plasma protein with anticoagulant properties 
(Schousboe, 1985, Harris et al., 1994, Hunt and Krilis, 1994). The properties of P,GPI 
that have been established are: binding to DNA and phosphoccllulose, lipoproteins, 
heparin, negatively charged phospholipid vesicles, intnilipid, platelets, mitochondria, and 
deoxycholate (Schousboe, 1985). Additionally, ll,GPI has been shown to inhibit contact 
activation of the _intrinsic blood coagulation pathway, ADP-mediated platelet aggregation, 
and prothrombinase activated platelets (Schousboe, 1985). The inhibiting effect of P,GPI 
on prothrombinase activity of resting platelets was not found to be inhibited by increasing 
the concentrations of Stuart-Prower Factor (Xa) and Platelet Factor V (Nimpf et al., 
1986). PaGPI is distributed among several plasma protein fractions. Approximately 17% 
is bound to high-density lipoprotein (HDL), 16% associated with chylomicrons and very­ 
low density lipoproteins (VLDL), 2% with low density lipoprotein (LDL), and the 
remaining 65% is not associated with lipoproteins (Nimpf et al., 1986). The 
5 
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concentration of p,GPI in the blood (0-300µg/ml) is the function of two codominant 
autosomal alleles, BgN and BgD with a BgN frequency of0.94 in Caucasians (Cleve and 
Ritter, 1969, Koppe et al., 1970, and Schousboe, 1985). The fifth domain of p,GPI has 
been found to contain a phospholipid binding site and a region that is recogniud by 
anticardiolipin antibodies (Hunt and Krilis, 1994). 
Additional studies have shown that the clinical manifestations of APS in patients 
with SLE associate more strongly with ap2GPI than with antiphospholipid antibodies. 
Cabiedes and colleagues (1995), demonstrated a strong association between a(3
2
GPI and 
clinical APS even in the absence of antiphospholipid antibodies (aPL). Furthermore, 
Blank and coworkers (1994) have shown that immunization of naive mice with p
2
GPI 
induced experimental APS. High titers of al31GPI antibodies were recorded in the sera of 
mice immunized with l31GPI. The immunized mice expressed clinical manifestations of 
APS consisting of prolonged aPPT's, significant thrombocytopcnia. reduced fecundity, 
increased fetal loss as well as a decrease in placental and embryo mean weights (Blank et 
al., 1994). These findings suggest a model in which antibodies from patients with APS 
bind to a cryptic epitope on p,GPI that is exposed after binding to a phospholipid (Hunt 
and Krilis, 1994, Wang et al., 1995) 
Current Evidence 
Mounting evidence pinpointed a�
1
GPI antibodies as the primary link to APS. 
Conflicting hypotheses emerged suggesting that p,GPI may be the antigen, p,GPI might 
modify the PL to fonn an epitope, that PL may modify p,GPI to fonn an epitope or that 
the epitope contains both moieties (Hunt and Krilis, 1994, Keil et al., 1995) In direct 
6 
conflict with the former reports, Gharavi and coworkers (1993) studied sera from 146 
patients with rheumatic diseases, including 75 that were aCL positive using ELISA, and 
determined that there was no increase in the binding to PiGPI coated wells compared to 
40 nonnal hwnan scra. 
Variations in the assay systems used may have been, at least partially, responsible 
for the conflicting data reported. Additionally, there was a wide range in the percentage 
of positive patients reported by investigators using (3
2
:GPI in their ELISA systems for the 
detection of APS. Conflicting conclusions may have risen from the coexistence of a 
number of auto antibodies in the sera to be assayed, particularly with SLE and related 
autoimmune disorders. Significant proportions of these patients have ACA, LA activity, 
antiendothelial cell antibodies, antiplatelet antibodies, anti-DNA antibodies and immune 
complexes (Shi et al., 1993). As mentioned previously, further confusion stemmed from 
early assumptions that LA and aCL were identical. Moreover, the role of 1}2GPI in the 
anitgen·antibody system was unclear. 
Monoclonal antibodies were used to confirm previous data regarding the functions 
of P2GPI in APS. Three families of monoclonal antibodies to purified p1GPI have been 
produced. All were found to react with p2GPI in ELISA and none reacted with negatively 
charged phospholipids. It should be noted, that one monoclonal antibody failed to 
recognize p2GPI bound to PL while the other two demonstrated enhanced binding when 
�,GP! was added to PL (Wagenknecht and Mcintyre, 1993). Monoclonal aCL antibodies 
have also been developed. These required p2GPI for anionic PL binding (Ichikawa et al., 
1994). Further, monoclonal aCL bound to solid phase �,GP! on polystyrene plates that 
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had carboxyl groups on their surface, but did not react with solid phase f}
2
GPI on ordinary 
polystyrene plates. Ichikawa and colleagues (1994) showed that the degree of binding 
was dose dependent and reached a plateau at p,GPI concentrations of 4-20 µg/ml . 
APS results in a serious derangement of hemostasis. Injury to the vessel wall 
causes platelets to adhere to the subendothelial structures, change their morphological 
structure and release the content of their granula and aggregate (Nimpf et al., 1986). The 
concurrent platelet aggregation and clot formation are the focal point of af}
2
GPI 
antibodies in APS. The antibodies are thought to predispose individuals to thrombosis 
through various mechan.isims. Anticardiolipin antibodies (aCL) and LA have been shown 
to be a discreet group of antiphospholipid antibodies (Pangborn, 1941 ). These antibodies 
often coexist although they are separable from the plasma. At physiological levels f}
2
GPI 
naturally inhibits the generation of factor Xa, although aCL arrests this action leading to 
unopposed factor X. generation and a prothrombotic state (Nimpf et al., 1986, K.andiah et 
al., 1996). LA immunoglobulins behave differently they have also been found to inhibit 
factor :X. generation in a similar manner (Nimpf et al., 1986, K.andiah et al., 1996). The 
- - 
elevated numbers of individuals with genetically-predetermined protein C and S 
deficiency has led some investigators to speculate on role of antibodies to these proteins 
in hemostasis. Malia and coworkers (1990), theorized that lupus like anticoagulants 
precipitate thrombosis through an effect on protein C. With activated protein C and S 
playing pivotal roles inhibiting blood coagulation through degradation of factors Va and 
VIII,. 
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Presently, there is a growing awareness that surfaces used to bind f3
2
GPI arc critical 
in presenting the epitope in such a manner that is recognized by af3
2
GPI antibodies. 
Matsuura and colleagues (1994) as well as Cabiedes and coworkers (1995), found that 
human SLE sera and sera from mice with APS recognize �,GPI only if polystyrene plates 
are previously oxygenated by irradiation. These studies were confirmed by Koike (1994). 
Experimental data showed that specificity for an epitope on f3
1
;GPI is expressed by a 
conformational change occurring when f32GPI interacts with an oxygen-substituted solid 
phase surface (Koike 1994). Galli and coworkers (1990) have demonstrated that the aPL 
cofactor was the target antigen for the aPL and that the antibody binding was proportional 
to the amount of cofactor coated on the microtiter wells in the absence of phospholipid. 
Collateral studies utilizing chemically activated polystyrene have been reported to bind 
proteins covalently, supporting the above findings (Keil et al., 1995). However, it should 
be noted that the latter did not observe a significant correlation between cofactor 
dependent aCL and a�2GPI antibodies, as was observed by Koike (1994). 
The use of polystyrene in anticardiolipin and 1}2GPI ELISA's has assumed a pivitol 
role in identifying patients prone to APS manifestations, albeit with varying degrees of 
success. Presently, few methodologies have been proposed for covalent binding of p
2
GPI 
in the ELISA system. Although, irradiation has been the method of choice for activating 
the surface of polystyrene, results have been inconsistent. Enhancing the previous ELISA 
systems through covalent binding (through the utilization of XenobindTM), application of 
the proper analyte (P,GPI), and performing consistent uniform technique have been 
critical to the ELISA system developed herein. Xenobind™ covalent microwell plates 
9 
provide a uniform swface of high binding capacity and low variability (Douglas and 
Monteith, 1994). Variation among previous assay systems employed may be due to 
several factors such as, effective blocking of the plate to prevent binding of the antigen or 
detector antibody to the plate surface, sample dilutions, consistent, thorough washing 
between steps to remove non-specifically bound material, and consistent, uniform 
immobilization of the capture antibody. Although the most notable and consequential 
variation presumably stems from a non-uniform binding surface for the analyte. 
As above, various authors have observed a correlation between P
2
GPI and APS. 
In the assay system herein. J}1GPI serves as the antigenic determinant whose cryptic 
epitope is revealed by its covalent binding to the solid surface ofXcnobind™. 
10 
Methods and Materials - Pilot Study 
Prior to the characterization of the novel assay described herein, the analytical and 
clinical relationship between human IgG autoantibodies to P,GPI and aCL antibodies was 
investigated. Sera were obtained from a bank of specimens submitted to the laboratory at 
St. Joseph's Hospital and Medical Center for routine aCL assay, and were maintained at 
-70°C (range -68 to -72°C). In addition to the patients on the Rheumatology Service the 
laboratory accepts diagnostic test referrals from all areas of the university-affiliated 780- 
bed urban medical center. This includes acute and long-term care in-patients and a 
number of out-patient satellite health centers, as well as from private physicians' offices 
in the region. 
Routine clinical measurement of aCL was made with kits from Reaads Medical 
Products (Westminster, CO, U.S.A.). The HRP secondary (anti-human IgG) antibody 
was also obtained from Reaads as part of the kit and used without modification, as were 
the substrate (3,3',5,5'-tetramethylbenzidine and H
1
0
1 
solution) and a stopping solution 
(1.25 M sulfuric acid). Rabbit anti-P2GPI was obtained from the Biotechnology Research 
Institute (Organon Teknika Corp., Rockville, MD, U.S.A.), HRP-conjugated goat anti­ 
rabbit lgG from Cappel Research Products (Organon Teknika Corp., Durham, NC, 
U.S.A.), and purified p,GPI was from Crystal Chem. Inc. (Chicago, IL, U.S.A). 
Chemically activated (Xenobindt») and untreated polystyrene microtiter plates were 
purchased from Xenopore Corp. (Saddle Brook, NJ, U.S.A.) and were used in strip 
fonnat containing 8 wells per strip. Gammabind G-Sephararose was obtained from 
II 
Pharmacia Corp. (Piscataway, NJ, U.S.A.). BSA (Fraction V) was purchased from 
Boehringer Mannheim Biochemicals (Indianapolis, IN, U.S.A.). Biotin-LC-hydrazide 
(Immunopore) and HRP-conjugated streptavidin were obtained from Pierce Chemical Co. 
(Rockford, IL, U.S.A.). 
ELISA was used in several formats. The clinical aCL assay yielding values in GPL 
(IgG anti-phospholipid) units standardized to the Louisville values (Cassulius et al., 
1991), was the commercial kit (described above) method. This was used without 
modification, and data obtained in this assay format are presented in GPL units. Wells 
for assay of fl,GPI binding were prepared by incubating (for 2 h at 37°C) I 00µ1 volumes 
of I Oµg/ml P,GPI, or biotinylated p,GPI dissolved in PBS to yield the final mass per well 
values indicated in the results. These plates were blocked with 3% BSA in PBS, which 
was also used as diluent and wash solution in the antH3
2
GPI assay. The Reaads HR.P­ 
anti-hwnan lgG and substrate were used as reconunended by the manufacturer to detect 
bound hwnan lgG. The rabbit IgG was detected using HRP-goat anti-rabbit IgG at a titer 
of 1:75000 followed by substrate reaction using the Reaads protocol. Biotinylated IgG 
was detected by HRP-streptavidin (30ng/ml) binding. For all binding studies, Reaads' 
substrate and stop solution were used, following the manufacturer's method. Absorbance 
was read at 450 mn in a BioTck Instruments, Inc. (Winooski, VT, U.S.A.) model EL307C 
microplate reader. 
Precipitins between the rabbit antibody and �2GPI were detected by double diffusion 
in agarose. Equivalence was optimally detected at an antigen range of 0.03-0.06mg/ml 
when antibody concentration was 1 mg/ml. A whole lgG fraction was purified from the 
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serum subject DB (see Table I) by ligand affinity chromatography using recombinant 
protein G (GanunaBind G-Sepharose). The eluted lgG was buffer-exchanged with PBS 
and concentrated to approximately the starting volume of serum as described previously 
(Cassulis et al., 1991). This lgG fraction was used to study precipitin formation by double 
diffusion against P,
2
GPI and in the elution experiments with high ionic strength, low pH 
citrate (HL citrate solution: sodium citrate/citric acid, pH 2.5, 1.4 M citrate). 
Methods and Materials - Establishment of de novo method. 
Commercially available products based on the Reaads kit were utilized to reveal a 
cryptic epitope for the binding of P,
2
GPI. The appropriate titer of horseradish peroxidase­ 
conjugated goat anti-human lgG (affinity-purified antibody containing -lg/L total 
protein, obtained from Cappel Research Products, Div. of Organon Teknika, Durham, 
NC; prod. no. 55252) was established. The absorbance of titers from 1:250.to 1:1250 of 
horseradish peroxidase-conjugated goat anti-human lgG to human lgG, were read at 
450run in a BioTek Instruments, Inc. (Winooski, VT, U.S.A.) model EL307C microplate 
reader. Xenobindw microtiter wells (Xenopore, Hawthorne, NJ) were used to provide the 
anionic surface for the binding of PlGPI. Utilizing two subjects, EE (low control) and 
DB (high control), volume fractions were plotted against the A.tso· Succeeding the 
volume fraction analysis, the samples and volume fractions were assayed for viability in 
subsequent days after thawing and days after harvest. 
Methods and Materials - Development of Standards 
Phlebotomy was perfonned on two subjects. Tue first subject (HRM-01), was a 35- 
year-old man with APS and positive laboratory test results for lupus anticoagulant (by 
13 
dilute Russell's viper venom method) and lgG anticardiolipin antibodies. The second 
subject (LRM-01), was a 24-year-old male graduate student in excellent health with no 
clinical or laboratory evidence of immunological or other disease. The protocol for 
harvesting one unit (500mL) of blood from these subjects was approved by the 
Institutional Review Board (responsible for the ethical conduct of experiments involving 
human subjects) at St. Joseph's Hospital and Medical Center. 
Blood was collected into standard citrate phosphate-dextrose-adenine (CPDA) 
donor collection bags (Miles, Elkhart, IN) containing O. l 9g of anhydrous citric acid, 
1.66g of sodium citrate (dihydrate), 0.14g of sodium phosphate, monobasic 
(monohydratc), 2.0lg of dextrose (monohydratc), and 0.017g of adenine. The nominal 
capacity of these bags is 450mL. Plasma was aseptically transferred to the satellite bag 
attached to the main collection bag. This resulted in the collection of 286mL of plasma 
from HRM-01 and 249mL of plasma from LRM-01. To achieve a target absorbance 
signal of-1.5 A at 450nm at a 1:100 dilution in our assay system, we further diluted the 
plasma preparation from HRM-01 with 52mL of outdated plasma from an anonymous 
blood donor and !OmL of CPDA prior to recalcification with 12mL of 0.9mol/L CaCl,. 
This plasma did not clot and was maintained as a plasma preparation. Plasma LRM-01 
was recalcified with 7.SmL ofCaC12solution, allowed to clot, and maintained as a serum 
preparation. Each preparation was aseptically divided into 50-uL aliquots that have been 
stored at -70°C (range -68 to -72°C) in our laboratory. Both HRM-01 and LRM-01 were 
nomeactive for antibodies to HIV, HTL V-1, hepatitis C and hepatitis B core antigen, and 
for hepatitis B surface antigen. 
14 
Using a modification of the method previously described (EL-Kadi et al., 1995), 
IOOuL to !Oug/mL P,GPI (Crystal Chemical, Chicago, IL) in phosphate-buffered saline 
(PBS, pH 7.4) was added to chemically activated microtiter wells (Xenobind™; 
Xenopore, Hawthorne, NJ), incubating for 2 hat 37°C, washing three times with 30 g/L 
bovine serum albumin (Cohn Fraction V; Boehringer Mannheim Biochemicals, 
lndanapolis, IN) in PBS (BSA/PBS), and then blocking with BSA/PBS (2h at 37°C). 
These antigen-coated plates were used soon after coating as they exhibited pseudo-first­ 
order decay with a t0_5 of -23 days after storage at 2-8°C. All assays were performed 
within 24h of antigen-coated plate preparation. 
The assay calibrators were diluted in 1:100 in BSA/PBS, then added (lOOuL) to 
antigen-coated wells and incubated for 15 min at room temperature (RT: 25 ± 1°C). 
After washing the wells three times with BSA/PBS, we further incubated (15 min, RT) 
the samples with lOOµL of horseradish peroxidase-conjugated goat anti-human IgG 
(1:500 dilution of stock affinity-purified antibody containing -lg/L total protein, 
obtained from Cappel Research Products, Div. of Organon Teknika, Durham, NC; prod. 
no. 55252). We then washed the wells as before with BSA/PBS and incubated each well 
with lOOµL of substrate solution, prepared by mixing a tetramethylbenzidine solution 
with an equal volume of H,0
1 
solution (both from Kirkegaard & Perry Labs., 
Gaithersburg, MD; prod. no. so. 76-00). After 10 min at RT, the reaction was stopped by 
adding 100µ1 of 1.25 mol/L sulfuric acid (reagent grade). We also measured A,� with a 
Model EL307C microtiter plate reader (Bio-tek Instruments, Winooski, VT) vs. a reagent 
blank in which BSA/PBS was substituted for diluted specimen. 
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Results • Pilot Study 
Sera were grouped into three categories: a reference group of apparently normal scra 
with low lgG aCL values (<22GPL units), a group of moderate binding sera containing 
those with additional 23 incremental GPL units (23-45 GPL units), and a high binding 
group, with � 46GPL units. Thus the latter two groups were considered positive for aCL. 
This was done to compare clinical features of APS in patients with high af3
2
GPI activity 
with those having low activity within the same range of aCL. 
The aCL values of 82 sera were distributed as follows: 44 had values within our 
laboratories reference (nonnal) interval of 0-22 GPL units: 38 sera had higher aCL values 
of 23-87 GPL units. The latter sera were considered positive and subdivided into two 
groups, a moderate binding group comprising sera ranging from 23-45 GPL units (n=18) 
and a high binding group with sera having � 46 GPL units (n-20). The distribution of 
al32GPI binding activity (in absorbance units) in these three groups are presented in 
Figure I. 
The low (s22GPL units) and moderate (23-45 GPL units) aCL groups had 
comparable ajl,GPI binding activities with the low group having 0.19 ± 0.15 (SD) and 
the moderate aCL group having 0.21 ± 0.09 absorbance units. The high aCL group (2'.: 
46GPL units) had significantly higher a�2GPI activity (0.56 ± 0.59). ANOVA indicated 
that the differences among the groups were significant at p < 0.0001, with a Newman­ 
Keuls test showing statistical significance (p<0.05) between the high GPL group and each 
of the other groups. 
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Figure I 
Anti�GPI (absorbancc unilS) in 3 groups or sera with low (�22 GPL).. moderate (23-4.5 OPL) and high 
(}46 GPL) aCL activity. Means t I SO arc shown by the bars {except for the �46 GPL group, in which 
case the mean minus I SD is below zero). The broken line is mean plus 2 SD for the reference group, 
taken as the upper limit for the reference interval. (normal range). 
A preliminary reference interval was established based on the mean ± 2SD 
(absorbance units) for the af3
2
GPI activity in the normal aCL group. Thus, values above 
0.49 absorbance units were considered positive. By this criterion, the sera subjects in the 
normal aCL group represented outliers. No subject in the moderate aCL was in this 
category, but six patients in the high aCL group were positive. A 3 x 2 table contingency 
table analysis of outliers ( >2SD above the mean of the low group) yielded X' = 12.61 
(p=0.002) compared to X2= 0.016 (p = 0.90) for the low and moderate groups alone in a 2 
x 2 analysis. 
A pilot series of 12 reference sera, six with high and six with low GPL values, was 
screened for reactivity with f32GPI bound to activated wells. The values obtained are 
shown in Table I. Two sera (DA and DB), both from patients with APS secondary to 
systemic lupus erythematosus (SLE), exhibited binding substantially higher than the BSA 
background control. At a higher serum titer (1:100) than that used in the experiment in 
Table I (1:50) on wells containing lµg of �2GPI, both sera again exhibited binding 
characteristics substantially different from other sera in the pilot group that were weakly 
or non-reactive {Fig. 2). 
We chose one of these high-binding sera (DB) to use as the index serum to compare 
the binding of f31GPI to activated wells with the binding to plain, unactivated polystyrene 
wells. These isothenns are shown in Figure 3a. In the unactivated wells, very little 
binding activity is observed over the entire range of f32GPI mass per well. The activated 
wells showed a sharp increase in activity over the range of 0.1-1.0µg per well, at which 
point maximum binding was observed. 
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Table 1. Ahsorbance Values for Anti·6� Activity in 12 
Reference Sera. 
Serum Diagnosis a CL Anti-J32GPl0 Control" 
(GPLunits) ("""""""' uniu) (ab.1orbance units) 
VT SLE 39 0.10 0.29 
DA SLE 47 > 2.0 0.35 
MJ FM 31 0.14 0.31 
DB SLE 91 > 2.0 0.24 
SB SLE 56 0.20 0.52 
GM n.d. 38 0.54 0.41 
AB n.d. 5 0.05 0.10 
CR n.d. 9 0.10 0.09 
JI n.d. 7 0.20 0.26 
HB n.d. 5 0.04 0.08 
KT n.d. 9 0.12 0.22 
NE n.d. 4 0.03 0.04 
All values arc duplicate measurements 
"'Abbreviations: SLE, systemic lupus erythematosis; FM, fibromyalgia; n.d, not determined. 
0Conditioru: 13:zGPI, lOµg/well with 3% BSA in .PBS; washed only with PBS only {no BSA); 
serum diluted 1:50. 
•Conditions: As above but without !3i:GPI, i.e. BSA only. 
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Figure 2 
Change in absorbance with titer of human scra in a binding assay for 
anti-b2GPI. b2GPI was added to activated polystyrene at l mg per 
well and incubated for 2 hr at 37EC. Wells were blocked with BSA 
under the same cooditions. Sera studied: DB ( circle), DA (diamond), 
KT (triangle), GM (inverted triangle) and vr (square). 
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Figure 3 
A) Absorption isothenns for �2GPI on activated (0) and unactivated (0) polystyrene. 
Activity detected with human serum (DB) IDII anti-human IgG. 
B) Absorption isothenns for �,GP! on activated (0) IDII unactivated (0) polystyrene. 
Activity detected with rabbit and anti-rabbit IgG. 
To investigate whether these observations were purely a demonstration of quantitative 
differences in binding, or whether epitope presentation was a surface-dependent 
phenomenon, we examined activity based on the recognition of bound antigen by a rabbit 
polyclonal IgG afl,GPI. This reagent exhibited liquid-phase reaction with ll,GPI as 
demonstrated by precipitin arcs in a double-diffusion system, whereas neither serum DB 
nor lgG purified from serum DB was reactive. These isotherms, shown in Figure 3b, 
again demonstrate near-maximal binding at lµg per well on the aclivated polystyrene. 
However, the unactivated wells also show substantial binding activity over the range of 1- 
IOµg per well. 
The apparent ability of P,GPI to bind to the unactivated polystyrene was confinned 
by the use of a biotin-avidin detection system (Fig.4), at a concentration of HRP­ 
streptavidin of 30nglml. Biotinylated ll,GPI bound to unactiviated polystyrene at nearly 
80% of its binding to activated polystyrene in the saturation region of the isotherm. 
Elution by HL citrate solution of either bound p,GPI or lgG ap,GPI was studied by using 
a series of procedures as described in Table 2. After initial assay of af3
2
GPI activity of the 
lgG fraction of serum DB (absorbance= 1.86, 100% activity by definition), a parallel set 
of wells was incubated with HL citrate (30 min at 25°C). Of these, half (two wells) were 
washed with PBS/BSA and assayed for lgG remaining. This procedure resulted in an 
absorbance of 0.09, demonstrating that over 95% of the lgG had been removed. Re­ 
incubation of the other two wells with the original IgG fraction, followed by re-assaying, 
resulted in an absorbance of 1.68, indicating a restoration of 90.3% of the original IgG 
af32GPI activity. 
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Figure 4 
Adsorption isothenns for biotinylated �,GP! on activated (0) and unactivated (0) 
polystyrene detected with HRP-streptadvidin at 30ng/ml 
Table 2. Protein Elution Profiles with HL Citrate Solution 
of the System IgG Anti-�GPI on Activated Polystyrene 
Number of 
Wells 
6:2 
Experimental Absorbance 
Procedure 
Complete System 1.86 
(IgG + f32GPI) 
Assay 
(HRP-anti IgG) 
Activity 
Yield 
100 
6:4 Assay 
(HRP-anti-IgG) 
4:2 Incubate with HL 
citrate I Assay 
0.09 4.8 
6:2 Reincubate with 
IgG 
2:2 Assay 1.68 90.3 
Absorbanc.c results arc means of duplicate measurements 
To determine the prevalence of ap
2
GPI in a larger group of sera we screened 113 
sera that had been submitted for aCI measurement. Binding of p2GPI above the cut-off of 
0.45 absorbance units (the mean± 2S.D. for 61 sera with GPL values within our normal 
range of 0-22 was (0.15 ± 0.30) was observed in only nine sera. Of these, six bad aCI 
measurements of 47 GPL or higher. 
Results - Establishment of de Novo Method 
Until this point standard kit reagents were used in the pilot study (Keil et al 1995). 
The kit reagents seemed the natural progression to the establishment of a de novo assay 
utilizing similar basic biochemical reactions. The novel assay utilized j3
2
GPI in place of 
cardiolipin. The titer of the horseradish peroxidase conjugated goat anti-human IgG 
(antibody containing !mg/ml total protein, Cappel Research Products, Durham, NC) was 
established. Figure 5, shows the optimal antibody titer to be used in succeeding assays to 
be 1 :500. In addition the volume fraction of EE and DB showed a linearity with a r = 
0.97 and S.,- 0.09, shown in Figure 6. In addition, the two samples of DB and EE were 
utilized to establish sample longevity in days _after harvest (Fig. 7), and in days after 
thawing (Fig. 8). 
Results of the Development of Standard Material 
From absorbance measurements obtained over the first 3 months of storage (n=21 ), 
A,,. was l.45 ± 0.24 (mean± SD, 95% confidence interval - l.34-1.56) for the HRM-01 
plasma calibrator and 0.11 ± 0.07 (95% confidence interval= 0.07-0.14) for the LRM-01 
serum calibrator. These values served as the basis for the assignment of arbitrary units to 
the materials, the units being a simple function of absorbance (A00) and dilution. Thus, a 
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Figure 7. Days after Harvest. 
Absorbance at 450nm plotted against days after harvest. Samples assayed; DB (•),EE 
(  T) and 0.5 volume fraction of DB and EE (A.). 
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Figure 8. Days after thawing. 
Absorbance at 4SOnm plotted against days after !hawing. Samples assayed; DB ( • ) , EE 
( 'Y ) and O.S volume fraction of DB and EE ( & ). 
standardized unit is defined as A450 times the reciprocal titer [titer"]. The resultant mean 
value for reference material HRM-01 was 145 SGU (standard lgG anti-P,GPI units), and 
LRM-01 was 11 SGU. 
The application of these materials in an immunoassay is presented as a typical five­ 
point calibration curve (Fig. 9). The values of the three intennediate calibrators are 
calculated from the assigned values of mixtures of HRM-01 and LRM-01. Thus 
undiluted LRM-01 and HRM-01 are equivalent to SGU - II and 145 respectively. 
Additional calibrators are as follows: 3 parts ofLRM-01 and I part ofHRM-01 yielding 
44 SGU, equal parts ofLRM-01 and HRM-01 yielding 78 SGU, and I part LRM-01 and 
3 parts HRM-01 yielding 112 SGU. The curve is linear (r - 0.99) over the applied 
range. The nonspecific binding of HRM-01, assessed by the signal from BSA-coated 
wells, is minimal (mean - 0.06 A,,., n - 20). 
Results of the Application of Reference Standards. 
To study the stability characteristics of 1}
2
GPI-coated microtiter plates stored and 
refrigerated at 2-8°C, the antigen coated w�ls were probed with four sera from subjects 
with APS. These were then subjected to the assay procedure at intervals of up to 125 
days. The data obtained from this experiment were normalized to percentage of 
maximum absorbance. These data, shown in Figure I 0, demonstrate excellent fit to a first 
order decomposition (r > 0.99 for all cases). The means± 1 SD were plotted against the 
natural logarithm of time (Fig. IO; inset); and the half-life (t a) was calculated from the 
rate constant (k' - -21.2d ·1), given by the slope of the line (r- 0.95, p< 0.05), yielding t 
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Standard Units Calibration curve generated from reference materials HR.OM-I and LRM­ 
O I. Results from a single run after the assignment of arbitrary units for the standards. 
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Normalized plots of absorbance versus time for stability study of antigen-coated plates 
after storage at 2-8°C. Inset shows regression line of Abs.na:c versus In time (In to., - 
2.76d Orto.,= 15.8 d). 
v. = 15.8 days. Thus 'in all studies that followed, the coated plates were used within 24hrs 
of the coating process, assuring at least 90% of the original activity. 
Two reference calibrators, (HRM-01 = 145 SGU and LRM-01 IISGU) were utilized 
as assay standards (Erickson et al., 1996). Three point standard curves with standards in 
duplicate were generated for each run. Acceptance criterion for a run was based on a 
value of r ::?:: .950. In Figure 11, the means and standard errors for 36 consecutive, 
accepted runs are depicted. 
Sera at three levels of activity were used to assess the precision (coefficient of 
variation [CV) ) of the assay both between (interassay) and within (inttaassay) runs. The 
data is presented in Table 3. To determine the effect of dilution on a specimen which lies 
beyond the high standard (at the screening titer of 1:100), a patient sample meeting the 
criterion was diluted serially. As can be seen from the results of the experiment, shown 
in Figure 12a, dilutions greater than 1:200 brought the value within range. The 
absorbance at each dilution was used to calculate SOU, which are shown as a function of 
titer in Figure 12b. The slope of this plot indicated no significant deviation from zero (p 
= 0.29); the mean value obtained was 426 SGU, with a CV of 10.9%. 
Results - Determination of a Reference Interval: 
In Table 4, the data on the healthy control cohort, from whom sera were collected for 
the detennination of the reference interval, are categorized by racial and ethnic 
background of the subjects. The distribution of SGU values obtained from the 204 
subjects in the reference sample are shown in Figure 13. Fourty-nine of the subjects 
(24%) had O SGU values as the distribution tailed to 54 SGU. As is apparent from the 
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Table 3. Precision of Immunoassay of IgG Anti-6lGPI at 
Three Levels. 
Intra-assay Precision 
Level n means SD CV(o/o) 
low 28 7.3 0.9 12.3 
mid 23 42 2.9 6.9 
high 22 113.7 9.4 8.3 
Values of means and standard deviations (SD) ate in standard IgG and Anti-f3
1
GPI units (SGU) 
Inter-assay Precision 
Level n means SD CV(0/o) 
low 19 7.9 2.8 35.4 
mid 19 40.3 6.4 15.9 
high 19 105.3 8.1 7.7 
Values of means and standard deviations (SD) ate in standard IgG and Anti-P2GPI units (SGU) 
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Dilutional linearity of an out of range specimen_ (A) Absoroanu at 4� at serial 
dilutions between titers of 1:100 and 1:1600. The value of the high standard (HRM-01) 
for this run is indicated. (B) Plot of three values obtained by conY<tsion to SGU 
recip<0cal titer. Shott solid lines to the right of the dotted regression line indicate the SD 
of SGU for these three points_ 
Tabli: 4, Distributi2n of 13..zGPI val:11e� (SGU) from Refi:ri:n!:!: 
Interval Cohort b.y Ethnicity 
Ethnicity I Race n (0/o) Mean Median Range 
White 152 (74.5) 7 6 0 -54  
Hispanic 18 (8.8) 8 7 0 -30  
Asian/ 15 (7.4) 10 8 0-49 
Pacific Island 
Black 10 (4.9) 12 13 0-26 
Undetermined 9 (4.4) 6 8 0 - 1 3  
Total 204 (100) 7 _ 7 0 -54  
Number of Individuals 
...... N (,.) .i:,.. u, 
0 0 0 0 0 0 
O tl .,, 
0 " -· -· ..3 la. = 
c: ::l. "1 
;,; O" " 
- " - <" e, w 
" 0 
"' " " 0 � .., 
-->. 
0 < 
0 " " " - ::-. = 
- 0 "  c.c .. ..  
� �  G')  
�  El  
..  
s:u Fractional Equivalent ..... I\.) 0 
... ::s 0 p p - 
,,. 
- 
0 
'" 
0 " .. · 0 =- I ,,. 
"t:P ' ' '< • .. N • 
" - • ,£'. G') 0 ,,(....) ,, 
" ,,� 0 "O 0 - • !" 
- 
..., 
0 � 
- • <O 
" - • .. 
"' 
en 
I " � Ill G) G') ' Gl  "' c:. .. 0 ,,. c: iil o 0 
c � c � 
0 m; 3 .. 
- " 
c 
"' 
� 
0 Iii " - g, c> ..
" 
- 
1 :r 
" '" iil alc. 0 
� ()'I a: £ 0 !!!. ::, � 
c> e 
"' w " 0 - ·..
- .. 
" e, 
bar graph, the distribution tested strongly non-Gaussian by the Kolmogorov-Smimov 
statistic (P< 0.0001). To include 95% of our values, as is nonnally done in the case of 
parametric reference intervals, the cumulative percentile plot (Fig.13, insert) was 
constructed. The value of SOU at the ninety-fifth percentile was determined and was 
taken to represent the upper limit of the reference interval, resulting in a range of 0-19 
sou. 
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Discussion 
The first test in which aPL were detectable was the complement fixation assay 
described by Wasserman in 1906. The antigen, bound by reagin was identified as 
cardiolipin by Pangborn in 1941. Subsequent worldwide distribution of anti-treponemal 
assays led to the observation of a phenomenon known as biological false positive 
serologic test for syphilis (BFP-STS). An acute and chronic BFP-STS were soon 
identified. Acute BFP-STS was usually infection induced, e.g. leprosy, tuberculosis, 
endocarditis ect. Chronic BFP-STS was observed to persist for greater than six months, 
and was associated with autoimmune, or lymphoproliferativc disease (Moore and Mohr, 
1952, Hasserick and Long, 1951 ). Additionally, pharmacologic agents such as 
procainamide, hydralazine, and chlorpromazide were observed to cause BFP-STS. 
Subsequently an unusual plasma constituent that inhibited in vitro coagulation, and 
paradoxically demonstrated an hypercoaguable state in vivo was detected. First termed 
the lupus anticoagulant (LA), the plasma constituent was later identified as an 
anticardiolipin antibody (aCL) (Feinstein and Rapaport, 1972 and Thiagarajan et at., 
1980). The advent of molecular biology led to the development of an anticardiolipin 
radioimmunoassay and standardiz.ation by Harris and colleagues in 1983. 
Antiphospholipid antibodies encompass at least three reactivities: BFP-STS, LA, 
and aCL. The latter two are associated with symptomatology although the significance 
continues to be debated (Gharavi et at., 1993, Alarcon-Segovia and Cabral, 1994, Blank 
et at., 1994, Hunt and Krilis, 1994, El-Kadi et at., 1995). The complications resulting 
from the autoimmune hypercoaguable state of APS has been associated with antibodies to 
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cardiolipin, and other anionic phospholipids (Hughes, 1983, Galli et al., 1990, Cabiedes 
et al., 1995). 
Recent evidence has identified p2GPI, once thought to be the cofactor for aCL as the 
phospholipid binding protein which is the true epitope for APS antibodies (Blank et al., 
1994, Najmey et al., 1996). Current data demonstrate that the recognition of�' GP! in the 
absence of phospholipid by human aCL is dependent on the surface to which f}
2
GPI is 
bound. When p2GPI is not bound to a solid phase, there appears to be a lack of 
recognition by human autoantibodies (Matsuura et al., 1994, Keil et al., 1995). Results 
have demonstrated that irradiated as well chemically activated- surfaces provide 
recognition of this epitope(s) (Matsuura et al., 1994, Keil et al., 1995). These surfaces 
appear to mimic the in vivo binding of f}
2
GPI to presumably anionic physiologic surfaces 
which reveal the proteins cryptic epitope, providing recognition of human autoantibodies. 
A pilot study was conducted to establish the foundation for a novel assay using 
f}2GPI as the antigen. This preliminary study made use of conventional methods to obtain 
aCL measurements from of 82 sera. Subsequently, the sera w� assayed for al-\
2
GPI 
activity through the use of chemically activated polystyrene, with BSA as a blocking 
agent. The reagent blanks demonstrated minimal binding; typically in the range of 0.02 - 
0.04 absorbance units. Further, the CV for the low, midlevel, and high intra-assay 
precision was 8.3%, 6.9% and 12.3% respectively. Additionally, the CV for the inter­ 
assay precision was 35.4%, 15.9"/o and 7 .7% for the low, midlevel and high respectively. 
Tue data from the pilot study suggest that substantial binding of f}
2
GPI does not 
occur in sera with aCL activity of less than 50 GPL units. Elevated 8'}2GPI activity was 
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found in 2 of the 62 sera with an a CL greater than 46 GPL units (Fig. I). Therefore, there 
was no significant correlation between cofactor dependent aCL and (3
2
GPI. Subsequently 
12 reference sera, six with high and six with low GPL values, were screened for reactivity 
with p,GPI bound to activated wells. Two of the subjects, DA and DB (Table!), had a 
higb GPL, as well higb ap,GPI absorbance units. Sera from DA and DB were chosen as 
the index sera to demonstrate absorption isotherms for p
2
GPI on activated and non­ 
activated polystyrene. Clearly, Figure 3, demonstrates the dependence ofan "activated" 
surface for the binding of fl,GPI. These results demonstrate binding to fl,GPI in untreated, 
hydrophobic polystyrene as well as activated polystyrene. Thus, the recognition of p,GPI 
on either chemically activated or irradiated polystyrene is a qualitative phenomenon, 
dependent not on the surface of the polystyrene but rather how the protein is bound to the 
surface. 
The chemically activated polystyrene works by covalently binding p
2
GPI. Covalent 
binding of the assay system was demonstrated utilizing elution experiments with HL 
citrate. (32GPI dependent on ionic interaction would have been removed..:_ Additionally 
9()0/o of the original lgG aJ32GPI activity can be reconstituted when af31GPI reactive IgG is 
reincubated with bound fl,GPI (Table 2). 
Prior to the work described herein, there were no standardized immunassays for the 
detection of antibodies to p2 GPI . In this study, a standard serial antibody titer (Fig. 5), 
and standard curves were established (Fig. 6). Also, the variability of standards over time 
(Fig. 7), and after thawing (Fig. 8), were investigated. 
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The application of these materials for the de novo assay is presented in a 5 point 
calibration curve (Fig. 9). The values of the three intermediate calibrators were calculated 
from the assigned values of the mixtures of HRM·Ol and LRM·Ol. The curve is linear 
(r - 0.99) over the applied aforementioned ranges. The non-specific binding of HRM-01 
assessed by the signal from the BSA-coated wells is minimal (mean - 0.06 A,,. and 
n = 20). Standard curves consistently demonstrated excellent linearity. The coefficient 
of determination (r') was minimal (0.95 limit of acceptance) and more typically in the 
range of 0.97 - 0.99 (Fig. 11 ). 
These data demonstrate the standardization of an assay for lgG antibodies to human 
P,GPI. Generally, the precision of the assay (fable I) is fairly good. The confidence 
intervals between arising from these measurements clearly suggest that discrimination 
between levels of al32GPI is satisfactory in this assay. The first standardized ap2GPI 
immunoassay and calibrators developed herein. can be used to develop international 
standards. Following the standardized detection of af32GPI antibodies, correlation's may 
be drawn between disease states with similar pathology. 
The pathologic, and complete in vivo physiological and molecular presentation 
l32GPI-al32GPI has not yet been elucidated. However, during the high mitotic and 
apoptoic rate of the embryo, apoptosis has been observed to be a source of immunogens 
(Vaishnaw et al.,1997). Several intervillous changes and fibrin changes have been 
reported in the placenta (Rosa et al., 1994). The mechanism of injury to the fetus by 
ap2GPI antibodies is variable, occurring on the trophoblast and villi surfaces of the 
placenta Thrombotic and infarcted areas are not uniform (Rosa et al., 1994) 
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Lockwood (I 986), observed an association between IgG-aCL subtype and fetal 
death, while intrauterine growth restriction was associated with IgM-aCL subtypes. 
Additionally, a high prevalence of antiphospholipid antibodies has been described in 
children with idiopathic cerebral ischemia (Schoenberg et al., 1978, Angelini et al., 
1994). It would be of interest to characteriz.e the ap,GPI antibodies with the standardiz.ed 
ELISA developed herein to determine a correlation between apoptosis and the generation 
of ap2GPI antibodies in these hypercoaguable states. 
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Conclusion 
Antiphospolipid Syndrome (APS) is a hypercoaguable state in which the following 
clinical manifestations may be present: arterial and venous thrombosis, livcdo reticularis, 
strokes, migraines, recurrent fetal loss, and thrombocytopenia. The underlying 
pathophysiologic process appear to be thrombotic in nature, although the mechanism 
responsible for the production of af32GPJ antibodies is unclear. However, some authors 
have theorized the externalization of phosphatidylserine during apoptosis plays a role. 
(Vaishnaw et al., 1994, Quasim et al., 1998). 
Laboratory characterization and detection of APS continues to be debated. Assays of 
p2GPI have used a variety of materials in the assay presentation system (Arvieux et al., 
1991, Koike 1994, Roubey et al., 1995, Keil et al., 1995). Lack of standardization has 
been well documented (Ekins 1991). The data presented herein describe the pcrfomumce 
characteristics and reference range of a standard ELISA for the detection of af32GPI 
antibodies. Therefore, standardized af32GPI units detected in hypercoaguable or 
pathological states, may begin to be correlated with aCL and LA assays previously 
standardized. 
During the development of the ELISA, the plates were used within 24hrs of 
preparation. Viability and decomposition after 24hrs was not evaluated. Moreover, it 
would be of interest to determine the response of these calibrators in assays that utilize 
irradiated plates and (or) noncommercial sources of f32GPI. 
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